# Detlev Riesner

> Detlev Riesner is a seed investor backing Biotechnology and Pharmaceutical. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Total investments: 2
- Last investment: Jul 2019
- Lead investor: 0%
- Last updated: Aug 2026

Detlev Riesner is a seed investor focused on Biotechnology and Pharmaceutical. Prof. Riesner has held the Chair of Biophysics at the Heinrich-Heine-University in Düsseldorf, Germany since 1980 and is Director of Technology at the University of Düsseldorf. He received his Ph.D. from the University of Braunschweig, Germany. Prof. Riesner is also a member of the Supervisory Board and a Director of Qiagen N.V., Netherlands.

## Contacts

5 contacts available for Detlev Riesner: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/detlev-riesner?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Pharmaceutical | 2 | 100% |
| Health Care | 1 | 50% |
| Therapeutics | 1 | 50% |
| Manufacturing | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pantherna Therapeutics | Pantherna Therapeutics is a privately-held biopharmaceutical Company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium. Pantherna is based in Hennigsdorf (Brandenburg) close toBerlin, Germany. | $4M | Seed | Jul 03, 2019 | https://pantherna-therapeutics.com/ |
| Numaferm | NUMAFERM challenges this paradigm. We have developed a reliable, cost-efficient manufacturing process that enables the reduction of production costs dramatically (up to 1000x). How is it possible? Our process is based on a well-designed microorganism that converts simple nutrients to peptides. It is the first-in-place bioprocess that serves as areliable platform for the production of peptides; independent of their sequence, length or functionality. |  | Seed | May 13, 2017 | http://numaferm.com/ |

2 of 2 investments shown.

## Co-investors
- [European Investment Fund](https://shizune.co/investors/profile/european-investment-fund) — VC Fund, 1 deal together
- [Evonik Venture Capital](https://shizune.co/investors/profile/evonik-venture-capital-gmbh) — VC Fund, 1 deal together
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Health Care Angel Investors in Germany](https://shizune.co/investors/health-care-angel-investors-germany)
- [Biotech Investors in Germany](https://shizune.co/investors/biotech-investors-germany)
- [Biotech Angel Investors in Germany](https://shizune.co/investors/biotech-angel-investors-germany)
- [Biotechnology Angel Investors in Germany](https://shizune.co/investors/biotechnology-angel-investors-germany)
- [Biotech Angel Investors in Europe](https://shizune.co/investors/biotech-angel-investors-europe)
- [Biotechnology Angel Investors in Europe](https://shizune.co/investors/biotechnology-angel-investors-europe)

## FAQ

### What does Detlev Riesner invest in?

Detlev Riesner invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Seed stage. Most of the 2 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Detlev Riesner?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Detlev Riesner last invest?

The most recent investment recorded for Detlev Riesner closed in Jul 2019. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co